Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL12 | P48061 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693167 | 0.78 | MAOB (0.41) | MEN1KMT2AACHETAAR1 | |
| SCHEMBL3242646 | 0.77 | RHEB (0.36) | MEN1KMT2AACHE | |
| SCHEMBL693164 | 0.74 | MEN1 (0.42) | MEN1KMT2AACHE | |
| SCHEMBL692988 | 0.74 | CTRC (0.46) | MEN1KMT2ATSHRPOLB | |
| SCHEMBL692593 | 0.74 | NR4A2 (0.48) | MEN1KMT2A | |
| SCHEMBL7708655 | 0.72 | CXCL12 (0.42) | CXCL12MAOATSHRMAPK1TAAR1 | |
| Anisole SCHEMBL6115627 | 0.70 | MEN1 (0.45) | MEN1KMT2A | |
| SCHEMBL692523 | 0.70 | MAPT (0.58) | FYNMEN1KMT2APOLB | |
| SCHEMBL7816115 | 0.70 | CXCL12 (0.65) | CXCL12FYNMAOAACHEBACE1 | |
| SCHEMBL692973 | 0.70 | MEN1 (0.47) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560654-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | claimed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | claimed |
| EP-2421368-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | claimed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | claimed |
| WO-2011133600-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | claimed |
| WO-2010123822-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | claimed |
| EP-2560654-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| EP-2421368-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| WO-2011133600-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010123822-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | CFTR, PKD1, PKD2 | CXCL12 2108/4885FYN 3851/4885MEN1 2920/4885 |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | SCN1A, CLIC1, CLCN2 | CXCL12 4737/4885FYN 3266/4885MEN1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.